Overview
Recent human studies found tissue sodium storage in patients with hyperaldosteronism that could be detected non-invasively by 23Na-MRI. Tissue sodium accumulation could be mobilized upon treatment of hyperaldosteronism. Besides, former animal studies applying chemical electrolyte analysis indicate that this aldosterone induced sodium storage might be accompanied by intracellular potassium loss. Wether such an intracellular tissue Potassium loss occurs in vivo in patients with hyperaldosteronism and if this deficiency can be corrected by treatment is unclear. The investigators will employ 39K-MR Imaging at 7Tesla to further assess this hypothesis.
Description
Patients diagnosed with primary hyperaldosteronism will be investigated using 23Na-MRI and 39K-MRI at 7 Tesla to assess tissue sodium and potassium content. Measurements will be conducted before treatment of hyperaldosteronism and three months after adrenal surgery or medical treatment (Spironolactone or Eplerenone). Furthermore, blood pressure, body water distribution (by bioimpedance spectroscopy), serum electrolytes as well as monocyte function will be assessed.
Eligibility
Inclusion Criteria:
- Primary Hyperaldosteronism diagnosed according to the endocrinological guidelines (J Clin Endocrinol Metab, May 2016)
Exclusion Criteria:
- Chronic kidney disease stage 3b and below (estimated GFR <30 ml/min according to CKD-EPI)
- Acute kidney injury
- Severe congestive heart failure (NYHA III and IV)
- Liver Cirrhosis (Child B and C)
- Pregnancy
- Contraindications for MRI measurements: cardiac Pacemaker, claustrophobia, etc.